Kazia’s Cantrixil Shows Signs of Effectiveness in Advanced Ovarian Cancer Trial

Kazia’s Cantrixil Shows Signs of Effectiveness in Advanced Ovarian Cancer Trial
Cantrixil, an investigative therapy which targets cancer cells that cause recurrence, shows promise as a treatment for ovarian cancer patients who failed at least two prior therapies, according to Australia-based Kazia Therapeutics (formerly Novogen). The treatment is being assessed alone and in combination with chemotherapy. To date, 60% of patients (three out of five) who received the first two cycles of Cantrixil have seen their disease stabilize, and one patient who received the combination achieved a partial response. Women with late-stage ovarian cancer who fail to benefit from existing chemotherapies have poor outcomes. Cantrixil is anticipated to provide a new treatment option for these women. The therapy candidate is composed of benzopyran, a molecule that targets all cancer cells, including those that cause cancer recurrence and metastasis, called tumor-initiating cells. This is thought to restore patients' sensitivity to chemotherapy. Besides investigating whether Cantrixil is safe, the trial (NCT02903771) will also determine the drug’s maximum tolerated dose. Researchers are administering it once a week through the peritoneum, or abdominal cavity. The study is being conducted in the United States and Australia, and is threefold. In part A, patients will receive ascending doses of Cantrixil alone to determine the treatment's maximum tolerated dose. After receiving Cantrixil for two cycles (with three weeks each), patients who tolerate the treatment may continue to rec
Subscribe or to access all post and page content.